Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthInteractive ToolsNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

Diagnostic Delays in Younger Women With Breast Cancer Are Mostly Patient-Related

April 11, 2024
By Gina Mauro
News
Article

Young patients with breast cancer were more likely to be the reason for diagnostic delays vs system delays, partly due to less concern for their symptoms.

"Better awareness on both the public and the practitioner end is needed regarding what is a concerning symptom, and that if things persist or change or get worse, follow-up is important," according to lead study author Katherine Fleshner, MD.

"Better awareness on both the public and the practitioner end is needed regarding what is a concerning symptom, and that if things persist or change or get worse, follow-up is important," according to lead study author Katherine Fleshner, MD.

Patient delays were the most common reasons for diagnostic delays in young women with breast cancer, according to survey results that were presented during a press briefing ahead of the 25th Annual American Society of Breast Surgeons Annual Meeting.1,2

Patient delays were 31.7% of the cause for diagnostic delays compared with 10.7% that were due to system delays. Additionally, predictors of patient delays in this patient population included painful lumps and having a first-degree relative with breast cancer.

Specifically, the median number of weeks that patients waited before seeking care was 2.0 weeks. Reasons for patient delay included patients not being worried about their symptoms (48.5%), waiting to see if it went away (32.9%), someone reassuring them their symptoms were not serious (6.9%), difficulty accessing timely care (6.4%), other priorities (3.6%), and fear (1.7%).

The wait time to a patient’s first doctor’s appointment was mostly less than 1 week, followed by 1 to 2 weeks, 3 to 4 weeks, and more than 4 weeks.

“Many of the reasons for patient delay had to do with patients not being aware that what they were experiencing could be related to malignancy,” lead study author Katherine Fleshner, MD, a postgraduate general surgical fellow of the University of Calgary in Canada, said in a press briefing ahead of the meeting. “The diagnostic journey overall can be complex in this population, mostly because there is a large percentage of benign breast findings in young women. Better awareness on both the public and the practitioner end is needed regarding what is a concerning symptom, and that if things persist or change or get worse, follow-up is important.”

Younger patients with breast cancer generally present differently than older patients and have more aggressive disease phenotypes. For example, younger patients are symptomatic and are often diagnosed at later stages when the disease has metastasized.

“We do know that this is a distinctly different population of patients compared with the typical postmenopausal ones who are diagnosed through screening,” Fleshner said.

Theoretical reasons for this are that younger women are not generally included in screening protocols, breast cancer is not often suspected, and there may be an element of diagnostic delay.

In the pan-Canadian study, young patients were defined as those who are younger than age 40 who present with newly diagnosed breast cancer, which Fleshner said is about 5% of all annual cases. Investigators sought to determine whether the diagnostic delay does exist in this younger patient population in Canada through the presentation of disease, the diagnostic process and timeline, and predictors of diagnostic delay.

Data were analyzed from a cohort of the Reducing the bUrden of Breast cancer in Young Women (RUBY) trial, which comprised patients 40 years and younger who had breast cancer and were enrolled at the time of their first meeting with a surgeon. Patients were prospectively recruited from 32 centers in the Yukon, British Columbia, Alberta, Saskatchewan, Manitoba, Ontario, Atlantic Canada, and Quebec regions, and 5 surveys were distributed to them via email and completed between 2015 and 2022. Follow-up was conducted over 5 years.

The surveys comprised questions on demographic data, personal history, medical history, how they came to their diagnosis, wait times, and their perception of their diagnosis process overall.

To define the diagnostic delay, investigators evaluated the time between the first symptom detected by the patient to the first contact with a health care provider (patient delay), first contact with the provider to first doctor’s appointment plus or minus investigations ordered (system delay), and also time from the first appointment to breast cancer diagnosis (system delay). Patient delay was defined as greater than 4 weeks, or 1 menstrual cycle, from onset of symptoms to first contact with a health care professional, while a system delay, was defined as more than 3 weeks from time of presentation to care to time of first imaging test, which was based on Canadian Partnership Against Cancer guidelines.

A total of 1148 patients were included on the study. The median age was 37 years (IQR, 33.9-39.0), most were Caucasian, and 43% were reported being otherwise healthy. A total of 36.8% of patients had a first-degree relative with cancer. Eighty-nine percent of patients had symptoms as their first detection of cancer—77.3% of whom had a palpable mass—followed by screening (8%), routine clinical breast cancer (2%), and incidental finding (1%). Reported symptoms included a painless lump (n = 516), painful lump (n = 208), multiple symptoms (n = 197), breast pain (n = 36), skin/nipple changes (n = 34), and nipple discharge (n = 27).

References

  1. Fleshner K, Yang F, Isherwood S, Xu, Quan ML. Diagnostic delay among young women with breast cancer. Presented at: 25th Annual American Society of Breast Cancer Surgeons Meeting; April 10-14, 2024; Orlando, FL.
  2. Young Women Frequently Delay Breast Cancer Assessment. The American Society of Breast Surgeons. News release. Published April 11, 2024. Accessed April 11, 2024. https://tinyurl.com/yc25bzp7

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
Breast oncologist Jade E. Jones, MD, says she tries to send patients with BRCA-mutant HR-positive TNBC to clinical trials that use PARP inhibitors.
Following progression on a CDK4/6 inhibitor, ascertaining the endocrine sensitivity of HR-positive/HER2-negative disease may inform sequential treatment.
T-DXd improved progression-free survival over standard chemotherapy among patients with HR-positive/triple-negative breast cancer in DESTINY-Breast04.
The use of chemotherapy trended towards improved recurrence-free intervals in older patients with high-risk tumors as determined via the MammaPrint assay.
Use of a pharmacist-directed resource appears to improve provider confidence and adverse effect monitoring for patients undergoing infusion therapy.
Reshma L. Mahtani, DO, describes how updates from the DESTINY-Breast09, ASCENT-04, and VERITAC-2 trials may shift practices in the breast cancer field.
Stage IV lung cancer may be curable based on the success of the DREAM Program, according to thoracic surgeon, Ankit Bharat, MBBS,
Related Content

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

Daniella Natanov;Sharon Koehler
July 1st 2025
Article


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.

Early Efficacy Seen With Gedatolisib-Based Therapies in Prostate/Breast Cancers

Tim Cortese
June 30th 2025
Article

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCRPC and mBC, respectively.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025
Article


21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article

Related Content

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

17 Salmonella and the Breast: A Literature Review of Salmonella-Induced Breast Abscesses

Daniella Natanov;Sharon Koehler
July 1st 2025
Article


Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.

Harnessing PIPAC to Improve Outcomes in Peritoneal Carcinomatosis

Benjamin J. Golas, MD
June 30th 2025
Podcast

Benjamin Golas, MD, discusses how the use of PIPAC may work in conjunction with systemic chemotherapy for those with peritoneal carcinomatosis.


Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCPRC and mBC, respectively.

Early Efficacy Seen With Gedatolisib-Based Therapies in Prostate/Breast Cancers

Tim Cortese
June 30th 2025
Article

Gedatolisib showed promising ORRs when given in combination with darolutamide and trastuzumab biosimilar in mCRPC and mBC, respectively.


Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.

Eliminating Racial Disparities in Guideline-Concordant Breast Cancer Care

Oluwadamilola “Lola” Fayanju, MD, MA, MPHS, FACS
April 21st 2025
Podcast

Findings highlight a need to incorporate diverse populations when developing guideline-concordant breast cancer care to achieve efficacy for all patients.


20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

20 Impact of Ribociclib Dose Reduction on Efficacy in Patients With Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast

Radhika Appaya;Erika P. Hamilton, MD;Thomas Decker;Hope S. Rugo, MD;Maria Fernandez Abad;Kevin Kalinsky, MD, MS;Qiang Liu;Mariya Rozenblit, MD;Barbara Radecka;Seock-Ah Im;Frances Visco;Alejandro Perez;Yogesh Chattar;Murat Akdere;Vaidyanathan Ganapathy;Sorcha Waters;Joyce O’Shaughnessy, MD
June 27th 2025
Article


21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

21 Distant Disease-Free Survival Across Key Subgroups From the Phase 3 NATALEE Trial of Ribociclib Plus a Nonsteroidal Aromatase Inhibitor in Patients With HR+/HER2− Early Breast Cancer

Sara A. Hurvitz, MD;Michal Jarzab;Montserrat Munoz Mateu;Erin Cobain;Jin Zhang;Arielle Medford;Alistair Ring;Priyanka Sharma, MD;Christian Schem, MD;Ionut Temciuc;Zheng Li;Juan Pablo Zarate;Denise A. Yardley, MD
June 26th 2025
Article

Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.